Opportunity Information: Apply for PA 10 031
Apply for PA 10 031
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Epigenetic Approaches in Cancer Epidemiology (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control.
- This funding opportunity was created on Oct 14, 2010 and posted on Nov 24, 2009.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education Small businesses For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI), under the National Institutes of Health (NIH), offered this Funding Opportunity Announcement (FOA) to support population-based cancer epidemiology research focused on epigenetics. The central aim was to encourage studies that measure and analyze epigenetic profiles, specifically DNA methylation patterns, histone modifications, and microRNA (miRNA) expression, and then test how those profiles relate to a persons risk of developing cancer across different human populations. In practical terms, the FOA sought research that could connect epigenetic variation or epigenetic change with cancer etiology, meaning the underlying causes and developmental pathways that lead to cancer, using real-world population data rather than only laboratory or animal models.
This opportunity used the NIH Research Project Grant (R01) mechanism, which is designed for more mature, hypothesis-driven projects with a well-developed study design, established methods, and clear analytic plans. NCI also noted that a companion announcement with the same scientific scope existed for the R21 mechanism (PA-10-032), which is typically used for earlier-stage, exploratory, or developmental work. The R01 version (PA-10-031) was therefore positioned for projects ready to conduct larger-scale epidemiologic investigations, often involving cohorts, case-control studies, or other population-based designs that can support robust inference about risk and variability across groups.
The work NCI wanted to stimulate centered on defining how epigenetic markers might influence cancer risk and how epigenetic patterns might differ by population, exposure history, or other risk-related characteristics. While the FOA summary highlights methylation, histone changes, and miRNA profiles, the broader implication is support for studies that can integrate these molecular measures into epidemiologic frameworks, such as examining associations with environmental exposures, lifestyle factors, aging, inflammation, infectious agents, or other determinants that may leave epigenetic signatures relevant to cancer development. The emphasis on population-based research also implies attention to issues like sample collection in large groups, measurement validity and reproducibility, appropriate comparison groups, and statistical approaches suitable for high-dimensional molecular data.
Awards were to be made only if funds were available and if enough high-quality applications were submitted, meaning there was no guaranteed number of grants funded. The FOA fell under CFDA 93.399 (Cancer Control) and did not require cost sharing or matching, which generally lowers barriers for applicants who might not have non-federal funds available to contribute.
Eligibility was broad and included many common research-performing organizations. Eligible applicants included public and state-controlled universities, private universities, nonprofit organizations (including both 501(c)(3) and certain nonprofits without 501(c)(3) status), small businesses, and other for-profit organizations (including those that are not small businesses). Government entities were also eligible, including state governments and certain federal agencies. Importantly, non-U.S. entities (foreign organizations) and regional organizations were listed as eligible as well, reflecting the reality that population-based cancer epidemiology and epigenetic research often benefits from international cohorts and diverse populations.
Key administrative details identify the announcement as PA-10-031, posted November 24, 2009, with an original and final closing date of January 7, 2013, and an archive date of February 7, 2013, meaning it is no longer active. The official information was hosted on the NIH grants site, and contact support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
1) What is this funding opportunity?
This was a National Cancer Institute (NCI), National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) to support population-based cancer epidemiology research focused on epigenetics, issued under FOA number PA-10-031.
2) What was the main goal of PA-10-031?
The central aim was to encourage studies that measure and analyze epigenetic profiles and test how those profiles relate to a person's risk of developing cancer across different human populations, using population-based (real-world) data.
3) What specific epigenetic measures were highlighted in the FOA?
The FOA specifically highlighted DNA methylation patterns, histone modifications, and microRNA (miRNA) expression profiles.
4) What kinds of research questions was NCI trying to stimulate?
The FOA emphasized work that connects epigenetic variation or epigenetic change to cancer etiology (the underlying causes and developmental pathways leading to cancer). It also emphasized defining how epigenetic markers might influence cancer risk and how epigenetic patterns might differ by population, exposure history, or other risk-related characteristics.
5) Does the FOA focus on laboratory or animal models?
No. The FOA stressed population-based cancer epidemiology approaches, meaning studies grounded in real-world human population data rather than only laboratory or animal models.
6) What grant mechanism was used?
This opportunity used the NIH Research Project Grant (R01) mechanism, which is generally intended for more mature, hypothesis-driven projects with a well-developed study design, established methods, and clear analytic plans.
7) Was there a related opportunity for smaller or earlier-stage projects?
Yes. NCI noted a companion announcement with the same scientific scope for the R21 mechanism (PA-10-032), which is typically used for earlier-stage, exploratory, or developmental work.
8) What types of study designs were implied as a fit for this R01?
The description positions the R01 version for larger-scale epidemiologic investigations, often involving cohorts, case-control studies, or other population-based designs that can support robust inference about risk and variability across groups.
9) What does "population-based" imply for the practical conduct of the research?
Based on the FOA description, "population-based" implies attention to issues such as sample collection in large groups, measurement validity and reproducibility, use of appropriate comparison groups, and statistical approaches suitable for high-dimensional molecular data.
10) What kinds of determinants or exposures could be examined in relation to epigenetic signatures?
The FOA suggested integrating molecular measures into epidemiologic frameworks, including examining associations with environmental exposures, lifestyle factors, aging, inflammation, infectious agents, or other determinants that may leave epigenetic signatures relevant to cancer development.
11) Was funding guaranteed?
No. Awards were to be made only if funds were available and if a sufficient number of high-quality applications were submitted. The FOA did not promise a guaranteed number of awards.
12) Did this FOA require cost sharing or matching funds?
No. The FOA did not require cost sharing or matching.
13) What CFDA number applied to this opportunity?
The FOA fell under CFDA 93.399 (Cancer Control).
14) Who was eligible to apply?
Eligibility was broad and included public and state-controlled universities, private universities, nonprofit organizations (including 501(c)(3) and certain nonprofits without 501(c)(3) status), small businesses, other for-profit organizations (including those that are not small businesses), and government entities such as state governments and certain federal agencies.
15) Were non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. entities (foreign organizations) and regional organizations were listed as eligible.
16) Why did the FOA include foreign and regional organizations as eligible?
The FOA description reflects that population-based cancer epidemiology and epigenetic research can benefit from international cohorts and diverse populations.
17) When was PA-10-031 posted?
The FOA was posted on November 24, 2009.
18) What were the closing dates for this FOA?
The FOA listed an original and final closing date of January 7, 2013.
19) Is PA-10-031 still active?
No. The FOA is no longer active. It had an archive date of February 7, 2013.
20) Where was the official FOA information hosted?
The official information was hosted on the NIH grants website.
21) Who was listed for support with access or linking issues?
Contact support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Education Health
Next opportunity: Epigenetic Approaches in Cancer Epidemiology (R21)
Previous opportunity: 2010 Challange Cost Share Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 031
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 031) also looked into and applied for these:
| Funding Opportunity |
|---|
| Epigenetic Approaches in Cancer Epidemiology (R21) Apply for PA 10 032 Funding Number: PA 10 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Transdisciplinary Research in Energetics and Cancer (U54) Apply for RFA CA 10 006 Funding Number: RFA CA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01) Apply for PA 10 035 Funding Number: PA 10 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R01) Apply for PAR 10 038 Funding Number: PAR 10 038 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 10 040 Funding Number: PAR 10 040 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 10 039 Funding Number: PAR 10 039 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Critical Illness and Injury in Aging (R03) Apply for PA 10 043 Funding Number: PA 10 043 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R01) Apply for PA 10 042 Funding Number: PA 10 042 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R21) Apply for PA 10 044 Funding Number: PA 10 044 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cancer Immunotherapy Trials Network (U01) Apply for RFA CA 10 007 Funding Number: RFA CA 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research on Integrity in Collaborative Research (R21) Apply for RFA RR 10 001 Funding Number: RFA RR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Coordination Center for Transdisciplinary Research in Energetics and Cancer (Limited Competition U01) Apply for RFA CA 10 501 Funding Number: RFA CA 10 501 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Support Opportunity for Addiction Research (SOAR) for New Investigators (R03) Apply for RFA DA 10 015 Funding Number: RFA DA 10 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Multifunctional Drug and Gene Delivery Systems (R01) Apply for PAR 10 048 Funding Number: PAR 10 048 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R01) Apply for RFA DA 10 006 Funding Number: RFA DA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cognitive Remediation Approaches to Improve Drug Abuse Treatment Outcomes (R21) Apply for RFA DA 10 007 Funding Number: RFA DA 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Academic Career Award (Parent K07) Apply for PA 10 058 Funding Number: PA 10 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pre Application for the 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) Apply for PAR 10 068 Funding Number: PAR 10 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 10 012 Funding Number: RFA DA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| AIDS Malignancy Clinical Trials Consortium (Limited Competition U01) Apply for RFA CA 10 502 Funding Number: RFA CA 10 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 031", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.